Therapeutic angiogenesis for critical limb ischaemia

Nature Reviews Cardiology

Volumn 10, Issue 7, 2013, Pages 387-396

  Annex, Brian H ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR 1; SCATTER FACTOR;

ANGIOGENESIS; ANGIOPLASTY; BLOOD FLOW; BYPASS SURGERY; CLINICAL TRIAL; GENE THERAPY; GENETICS; HUMAN; LIMB AMPUTATION; LIMB ISCHEMIA; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; REVIEW; SYSTEMS BIOLOGY;

ANGIOGENIC PROTEINS; CRITICAL ILLNESS; GENETIC THERAPY; HEMODYNAMICS; HUMANS; ISCHEMIA; LOWER EXTREMITY; NEOVASCULARIZATION, PHYSIOLOGIC; RECOVERY OF FUNCTION; REGIONAL BLOOD FLOW; SYSTEMS BIOLOGY; TREATMENT OUTCOME;

EID: 84881114106     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2013.70     Document Type: Review

References (83)

1. Belch, J. J. et al. Critical issues in peripheral arterial disease detection and management: A call to action. Arch. Intern. Med. 163, 884-892 (2003).
2. Norgren, L. et al. Inter-society consensus for the management of peripheral arterial disease (TASCII). J. Vasc. Surg. 45 (Suppl. S), S5-S67 (2007).
3. Roger, V. L. et al. Heart disease and stroke statistics-2011 update: A report from the American Heart Association. Circulation 123, e18-e209 (2011).
4. Beckman, J. A., Creager, M. A. & Libby, P. Diabetes and atherosclerosis: Epidemiology, pathophysiology, and management. JAMA 287, 2570-2581 (2002).
5. Dormandy, J., Heeck, L. & Vig, S. The fate of patients with critical leg ischemia. Semin. Vasc. Surg. 12, 142-147 (1999).
6. Hankey, G. J., Norman, P. E. & Eikelboom, J. W. Medical treatment of peripheral arterial disease. JAMA 295, 547-553 (2006).
7. Hiatt, W. R., Hoag, S. & Hamman, R. F. Effect of diagnostic criteria on the prevalence of peripheral arterial disease. The San Luis Valley Diabetes Study. Circulation 91, 1472-1479 (1995).
8. Hiatt, W. R. Medical treatment of peripheral arterial disease and claudication. N. Engl. J. Med. 344, 1608-1621 (2001).
9. Fontaine, R., Kim, M. & Kieny, R. Surgical treatment of peripheral circulation disorders [German]. Helv. Chir. Acta 21, 499-533 (1954).
10. Dormandy, J. A. & Rutherford, R. B. Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC). J. Vasc. Surg. 31, S1-S296 (2000).
11. Brass, E. P. et al. Parenteral therapy with lipo-ecraprost, a lipid-based formulation of a PGE1 analog, does not alter six-month outcomes in patients with critical leg ischemia. J. Vasc. Surg. 43, 752-759 (2006).
12. Ouriel, K. Peripheral arterial disease. Lancet 358, 1257-1264 (2001).
13. Berceli, S. A. et al. Surgical and endovascular revision of infrainguinal vein bypass grafts: Analysis of midterm outcomes from the PREVENT III trial. J. Vasc. Surg. 46, 1173-1179 (2007).
14. Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1, 27-31 (1995).
15. Simons, M. Angiogenesis: Where do we stand now? Circulation 111, 1556-1566 (2005).
16. Losordo, D. W. & Dimmler, S. Therapeutic angiogenesis and vasculogenesis for ischemic disease. Part I: Angiogenic cytokines. Circulation 109, 2487-2491 (2004).
17. Asahara, T. et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 275, 964-967 (1997).
18. Ito, W. D. et al. Angiogenesis but not collateral growth is associated with ischemia after femoral artery occlusion. Am. J. Physiol. 273, H1255-H1265 (1997).
19. Robbins, J. L. et al. Relationship between leg muscle capillary density and peak hyperemic blood flow with endurance capacity in peripheral artery disease. J. Appl. Phys. 111, 81-86 (2011).
20. Askew, C. D. et al. Skeletal muscle phenotype is associated with exercise tolerance in patients with peripheral arterial disease. J. Vasc. Surg. 41, 802-807 (2005).
21. Mitchell, R. G. et al. Increased levels of apoptosis in gastrocnemius skeletal muscle in patients with peripheral arterial disease. Vasc. Med. 12, 285-290 (2007).
22. Duscha, B. D. et al. Angiogenesis in skeletal muscle precede improvements in peak oxygen uptake in peripheral artery disease patients. Arterioscler. Thromb. Vasc. Biol. 31, 2742-2748 (2011).
23. Gardner, A. W. & Killewich, L. A. Lack of functional benefits following infrainguinal bypass in peripheral arterial occlusive disease patients. Vasc. Med. 6, 9-14 (2001).
24. Schaper, W. & Buschmann, I. Arteriogenesis, the good and bad of it. Cardiovasc. Res. 43, 835-837 (1999).
25. Chalothorn, D. et al. Collateral density, remodeling, and VEGFA expression differ widely between mouse strains. Physiol. Genomics 30, 179-191 (2007).
26. de Muinck, E. D. & Simons, M. Re-evaluating therapeutic neovascularization. J. Mol. Cell. Cardiol. 36, 25-32 (2004).
27. Heil, M., Ziegelhoeffer, T., Mees, B. & Schaper, W. A different outlook on the role of bone marrow stem cells in vascular growth: Bone marrow delivers software not hardware. Circ. Res. 94, 573-574 (2004).
28. Luttun, A. & Carmeliet, P. De novo vasculogenesis in the heart. Cardiovasc. Res. 58, 378-389 (2003).
29. Mac Gabhann, F., Qutub, A. A., Annex, B. H. & Popel, A. S. Systems biology of pro-angiogenic therapies targeting the VEGF system. Wiley Interdiscip. Rev. Syst. Biol. Med. 2, 694-707 (2010).
30. Ferrara, N. Vascular endothelial growth factor. Arterioscler. Thromb. Vasc. Biol. 29, 789-791 (2009).
31. Vempati, P. Mac Gabhann, F. & Popel, A. S. Formation of VEGF isoform-specific spatial distributions governing angiogenesis: Computational analysis. BMC Syst. Biol. 5, 59 (2011).
32. Qutub, A. A., Mac Gabhann, F., Karagiannis, E. D., Vempati, P. & Popel, A. S. Multiscale models of angiogenesis. IEEE Eng. Med. Biol. Mag. 28, 14-31 (2009).
33. Stefanini, M. O., Wu, F. T., Mac Gabhann, F. & Popel, A. S. A compartment model of VEGF distribution in blood, healthy and diseased tissues. BMC Syst. Biol. 2, 77 (2008).
34. Wu, F. T. et al. Computational kinetic model of VEGF trapping by soluble VEGF receptor1: Effects of transendothelial and lymphatic macromolecular transport. Physiol. Genomics 38, 29-41 (2009).
35. Hazarika, S. et al. Impaired angiogenesis after hindlimb ischemia in type 2 diabetes mellitus: Differential regulation of vascular endothelial growth factor receptor 1 and soluble vascular endothelial growth factor receptor 1. Circ. Res. 101, 948-956 (2007).
36. Mac Gabhann, F. & Popel, A. S. Model of competitive binding of vascular endothelial growth factor and placental growth factor to VEGF receptors on endothelial cells. Am. J. Physiol. Heart Circ. Physiol. 286, H153-H164 (2004).
37. Mac Gabhann, F., Annex, B. H. & Popel, A. S. Gene therapy from the perspective of systems biology. Curr. Opin. Mol. Ther. 12, 570-577 (2010).
38. Wu, F. T. et al. VEGF and soluble VEGF receptor1 (sFlt1) distributions in peripheral arterial disease: An in silico model. Am. J. Physiol. Heart Circ. Physiol. 298, H2174-H2191 (2010).
39. Folkman, J. Tumor angiogenesis: Therapeutic implications. N. Engl. J. Med. 285, 1182-1186 (1971).
40. Senger, D. R. et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219, 983-985 (1983).
41. Rajagopalan, S. et al. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: A phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation 108, 1933-1938 (2003).
42. de Vries, C. et al. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 255, 989-991 (1992).
43. Isner, J. M. et al. Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Lancet 348, 370-374 (1996).
44. Lederman, R. J. et al. Therapeutic angiogenesis with recombinant fibroblast growth factor2 for intermittent claudication (the TRAFFIC study): A randomised trial. Lancet 359, 2053-2058 (2002).
45. Simons, M. et al. Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor2: Double-blind, randomized, controlled clinical trial. Circulation 105, 788-793 (2002).
46. Grines, C. L. et al. Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris. Circulation 105, 1291-1297 (2002).
47. Kusumanto, Y. H. et al. Treatment with intramuscular vascular endothelial growth factor gene compared with placebo for patients with diabetes mellitus and critical limb ischemia: A double-blind randomized trial. Hum. Gene Ther. 17, 683-691 (2006).
48. Witzenbichler, B. et al. Intramuscular gene transfer of fibroblast growth factor1 using improved pCOR plasmid design stimulates collateral formation in a rabbit ischemic hindlimb model. J. Molec. Med. 84, 491-502 (2006).
49. Comerota, A. J. et al. Naked plasmid DNA encoding fibroblast growth factor type 1 for the treatment of end-stage unreconstructible lower extremity ischemia: Preliminary results of a phase I trial. J. Vasc. Surg. 35, 930-936 (2002).
50. Baumgartner, I. et al. Local gene transfer and expression following intramuscular administration of FGF1 plasmid DNA in patients with critical limb ischemia. Mol. Ther. 17, 914-921 (2009).
51. Nikol, S. et al. Therapeutic angiogenesis with intramuscular NV1FGF improves amputation-free survival in patients with critical limb ischemia. Mol. Ther. 16, 972-978 (2008).
52. Belch, J. et al. Effect of fibroblast growth factor NV1FGF on amputation and death: A randomised placebo-controlled trial of gene therapy in critical limb ischaemia. Lancet 377, 1929-1937 (2011).
53. Tashiro, K. et al. Deduced primary structure of rat hepatocyte growth factor and expression of the mRNA in rat tissues. Proc. Natl Acad. Sci. USA 87, 3200-3204 (1990).
54. Hayashi. S. et al. Potential role of hepatocyte growth factor, a novel angiogenic growth factor, in peripheral arterial disease: Downregulation of HGF in response to hypoxia in vascular cells. Circulation 100 (19 Suppl.), II301-II308 (1999).
55. Powell, R. J. et al. Results of a double-blind, placebo-controlled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb perfusion in patients with critical limb ischemia. Circulation 118, 58-65 (2008).
56. Powell, R. J. et al. Safety and efficacy of patient specific intramuscular injection of HGF plasmid gene therapy on limb perfusion and wound healing in patients with ischemic lower extremity ulceration: Results of the HGF0205 trial. J. Vasc. Surg. 52, 1525-1530 (2010).
57. Shigematsu, H. et al. Randomized, double-blind, placebo-controlled clinical trial of hepatocyte growth factor plasmid for critical limb ischemia. Gene Ther. 17, 1152-1161 (2010).
58. Creager, M. A. et al. Effect of hypoxia-inducible factor-1alpha gene therapy on walking performance in patients with intermittent claudication. Circulation 124, 1765-1773 (2011).
59. Chung, A. S., Lee, J. & Ferrara, N. Targeting the tumour vasculature: Insights from physiological angiogenesis. Nat. Rev. Cancer 10, 505-514 (2010).
60. Ferrara, N. Vascular endothelial growth factor and age-related macular degeneration: From basic science to therapy. Nat. Med. 16, 1107-1111 (2010).
61. Tang, G. L. et al. The effect of gradual or acute arterial occlusion on skeletal muscle blood flow, arteriogenesis, and inflammation in rat hindlimb ischemia. J. Vasc. Surg. 41, 312-320 (2005).
62. Waters, R. E., Terjung, R. L., Peters, K. G. & Annex, B. H. Preclinical models of human peripheral arterial occlusive disease: Implications for investigation of therapeutic agents. J. Appl. Physiol. 97, 773-780 (2004).
63. Dokun A. O. et al. A quantitative trait locus (LSq1) on mouse chromosome 7 is linked to the absence of tissue loss after surgical hindlimb ischemia. Circulation 117, 1207-1215 (2008).
64. Allen, J. D. et al. Plasma nitrite response and arterial reactivity differentiate vascular health and performance. Nitric Oxide 20, 231-237 (2009).
65. Sun, L., Bai, Y. & Du, G. Endothelial dysfunction-an obstacle of therapeutic angiogenesis. Ageing Res. Rev. 8, 306-313 (2009).
66. Tuomisto, T. T. et al. HIFVEGFVEGFR2, TNF-alpha and IGF pathways are upregulated in critical human skeletal muscle ischemia as studied with DNA array. Atherosclerosis 174, 111-120 (2004).
67. Nakamura, T. et al. Myocardial protection from ischemia/reperfusion injury by endogenous and exogenous HGF. J. Clin. Invest. 106, 1511-1519 (2000).
68. Yamamura, Y. et al. IGFI differentially regulates Bcl-xL and Bax and confers myocardial protection in the rat heart. Am. J. Physiol. Heart Circ. Physiol. 280, H1191-H1200 (2001).
69. Helisch, A. et al. Impact of mouse strain differences in innate hindlimb collateral vasculature. Arterioscler. Thromb. Vasc. Biol. 26, 520-526 (2006).
70. Reny, J. L. et al. The factor II G20210A gene polymorphism, but not factor V Arg506Gln, is associated with peripheral arterial disease: Results of a case-control study. J. Thromb. Haemost. 2, 1334-1340 (2004).
71. Fontana, P. et al. P2Y12 H2 haplotype is associated with peripheral arterial disease: A case-control study. Circulation 108, 2971-2973 (2003).
72. Fowkes, F. G. et al. Fibrinogen genotype and risk of peripheral atherosclerosis. Lancet 339, 693-696 (1992).
73. Gudmundsson, G. et al. Localization of a gene for peripheral arterial occlusive disease to chromosome 1p31. Am. J. Hum. Genet. 70, 586-592 (2002).
74. Murabito, J. M. et al. Association between chromosome 9p21 variants and the ankle-brachial index identified by a meta-analysis of 21 genome-wide association studies. Circ. Cardiovasc. Genet. 5, 100-112 (2012).
75. Da Silva, A. et al. The Basle longitudinal study: Report on the relation of initial glucose level to baseline ECG abnormalities, peripheral artery disease, and subsequent mortality. J. Chronic Dis. 32, 797-803 (1979).
76. Willigendael, E. M. et al. Influence of smoking on incidence and prevalence of peripheral arterial disease. J. Vasc. Surg. 40, 1158-1165 (2004).
77. Scholz, D. et al. Contribution of arteriogenesis and angiogenesis to postocclusive hindlimb perfusion in mice. J. Mol. Cell. Cardiol. 34, 775-787 (2002).
78. Fukino, K., Sata, M., Seko, Y., Hirata, Y. & Nagai, R. Genetic background influences therapeutic effectiveness of VEGF. Biochem. Biophys. Res. Commun. 310, 143-147 (2003).
79. Rissanen, T. T. & Ylä-Herttuala, S. Current status of cardiovascular gene therapy. Mol. Ther. 15, 1233-1247 (2007).
80. Kotchey, N. M. et al. A potential role of distinctively delayed blood clearance of recombinant adeno-associated virus serotype 9 in robust cardiac transduction. Mol. Ther. 19, 1079-1089 (2011).
81. Hernandez, Y. J. et al. Latent adeno-associated virus infection elicits humoral but not cell-mediated immune responses in a nonhuman primate model. J. Virol. 73, 8549-8558 (1999).
82. Saqib, A. et al. Adeno-associated virus serotype 9mediated overexpression of extracellular superoxide dismutase improves recovery from surgical hind-limb ischemia in BALB/c mice. J. Vasc. Surg. 54, 810-818 (2011).
83. Katwal, A. B. et al. Adeno-associated virus serotype 9 efficiently targets ischemic skeletal muscle following systemic delivery in a mouse model of peripheral arterial disease [abstract A14001]. Circulation 124, A14001 (2011).